Related Experiment Video
Updated: Apr 29, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing
Gregory A Kline1, Janice L Pasieka, Adrian Harvey
1Division of Endocrinology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract:
This retrospective review examined all primary aldosteronism (PA) adrenal vein sampling (AVS), diagnoses, and outcomes from an endocrine hypertension unit where confirmatory testing was abandoned in 2005 to determine the potential rate of false-positive diagnoses. Patients with outcome-verified PA (surgical patients) were compared with patients with high-probability PA (nonsurgical but high aldosterone-renin ratio, imaging abnormalities, and/or hypokalemia) or possible PA (nonsurgical, no features besides mild elevation of aldosterone-renin ratio, a potential false diagnosis of PA). Of 83 patients, 58% had unilateral PA and 42% had bilateral aldosteronism. Less than 3% of the cohort showed bilateral aldosteronism without hypokalemia or computed tomographic findings, potentially representing the false-positive PA diagnosis rate with omission of confirmatory tests in this population. In a hypertension referral unit enriched in high-probability PA cases and where high AVS success is achieved, omission of a PA confirmatory test yields a high rate of surgical diagnosis with few potential false-positive diagnoses.
More Related Videos
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Cushing Syndrome I: Introduction
Antihypertensive Drugs: Action of β1 Blockers
Cushing Syndrome II: Pathophysiology
Hormonal Regulation

